Validated ultra-performance liquid chromatography tandem mass spectrometry method for the determination of pramipexole in human plasma

Journal of Chromatographic Science

Volumn 48, Issue 10, 2010, Pages 811-818

  Yadav, Manish ^a,b   Rao, Rajasekhar ^a   Kurani, Hemal ^a   Rathod, Jaysukh ^a   Patel, Rakesh ^a   Singhal, Puran ^a   Shrivastav, Pranav S ^b  

^a Veeda Clinical Research India   (India)

^b GUJARAT UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149311111     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/48.10.811     Document Type: Article

References (21)

1. R. Constantinescu. Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr. Dis. Treat. 4:337-352 (2008).
2. P.L. McCormack, and M.A. Siddiqui. Pramipexole: in restless legs syndrome. CNS Drugs. 21: 429-437 (2007).
3. J. Mierau, F. Schneider, H. Ensinger, C. Chio, M. Lajiness, and R. Huff. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol. 290: 29-36 (1995).
4. M. Martínez-Corral, and J. Kulisevsky. Pramipexole and Parkinson's disease, an update. Rev. Neurol. 46: 49-52 (2008).
5. R. Danzeisen, B. Schwalenstoecker, F. Gillardon, E. Buerger, V. Krzykalla, K. Klinder, L. Schild, B. Hengerer, A.C. Ludolph, C. Dorner-Ciossek, and L. Kussmaul. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2× [(+)2-amino-4,5,6,7-tetrahydro-6-L-propyl amino-benzathia- zole dihydrochloride. J. Pharmacol. Exp. Ther. 316:189-199 (2006).
6. K.M. Biglan, and R.G. Holloway. A review of pramipexole and its clinical utility in Parkinson's disease. Expert Opin. Pharmacother.3:197-210 (2002).
7. D. Deleu, M.G. Northway, and Y. Hanssens. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 41: 261-309 (2002).
8. G. Srinubabu, K. Jaganbabu, B. Sudharani, K. Venugopal, G. Girizasankar, and J.V.L.N.S. Rao. Development and validation of a LC method for the determination of pramipexole using an experimental design. Chromatographia 64: 95-100 (2006).
9. B. Jancic, M. Medenica, D. Ivanovic, and A. Malenovic. Experimental design in chromatographic analysis of pramipexole and its impurities. Acta Chim. Slov. 54: 49-54 (2007).
10. D.B. Pathare, A.S. Jadhav, and M.S. Shingare. Validated chiral liquid chro- matographic method for the enantiomeric separation of pramipexole dihy- drochloride monohydrate. J. Pharm. Biomed. Anal. 41:1152-1156 (2006).
11. Y.Y. Lau, G.D. Hanson and N. Ichhpurani. Determination of pramipexole (U-98,528) in human plasma and urine by high-performance liquid chro- matography with electrochemical and ultraviolet detection. J. Chromatogr. B 683: 217-223 (1996).
12. A. Musenga, E. Kenndler, E. Morganti, F. Rasi, and M.A. Raggi. Analysis of the anti-Parkinson drug pramipexole in human urine by capillary elec- trophoresis with laser-induced fluorescence detection. Anal. Chim. Acta 626: 89-96 (2008).
13. Y.Y. Lau, J.M. Selenka, G.D. Hanson, R. Talaat, and N.E. Ichhpurani. Determination of pramipexole (U-98,528) in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ioniza- tion tandem mass spectrometry. J. Chromatogr. B 683: 209-216 (1996).
14. R.V. Nirogi, V. Kandikere, W. Shrivastava, K. Mudigonda, S. Maurya, and D. Ajjala. Quantification of pramipexole in human plasma by liquid chro- matography tandem mass spectrometry using tamsulosin as internal standard. Biomed. Chromatogr. 21:1151-1158 (2007). (Pubitemid 350200894)
15. D.V. Bharathi, K.K. Hotha, P.V. Sagar, S.S. Kumar, A. Naidu, and R. Mullangi. Development and validation of a sensitive LC-MS/MS method with electro- spray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. Biomed. Chromatogr. 23:212-218 (2009).
16. S.M. ChesnutandJ.J. Salisbury. The role of UHPLC in pharmaceutical development. J. Sep. Sci. 30: 1183-1190 (2007).
17. N. Wu and A.M. Clausen. Fundamental and practical aspects of ultrahigh pressure liquid chromatography for fast separations. J. Sep. Sci. 30: 1167-1182 (2007).
18. Guidance for Industry, Bionanlytical Method Validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001.
19. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75:3019-3030 (2003).
20. Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), April 1996.
21. M.L. Rocci, Jr., V. Devanarayan, D.B. Haughey, and P. Jardieu. Confirmatory Reanalysis of Incurred Bioanalytical Samples. AAPS Journal 9: E336-E343 (2007).